For observational studies, the initial quality of the evidence is low. The quality of the evidence is lowered in the event of study limitations; important inconsistencies in results across Guideline Chapter 4 Blood pressure management in kidney transplant recipients Cochrane review None relevant SoF table None Clinical question In kidney transplant recipients, what antihypertensive agents improve ef cacy outcomes and reduce adverse effects? Population Kidney transplant recipients, adult and children Intervention RAS inhibition (ACEi, ARB, aldosterone antagonists), and non-RAS inhibition (alpha-blockers, beta-blockers, CCBs, diuretics, DRI) Comparator Placebo or standard of care Outcomes Critical and important outcomes listed in Table 1 Other outcomes reported: BP Study design RCTs Cochrane review Cross NB, et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database of Systematic Reviews. SoF table Supplementary Tables S33 S39 and S92 S106 Clinical question In kidney transplant recipients with chronic hyperkalemia, do potassium binders compared to placebo or standard of care improve clinically relevant outcomes and decrease adverse effects? Population Kidney transplant recipients with chronic hyperkalemia Intervention Potassium binders Comparator Placebo/standard of care Outcomes Critical and important harms listed in Table 1 Study design RCTs Cochrane review Natale P, et al. 2020. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database of Systematic Reviews. 2020:6:CD013165.381 SoF table None Guideline Chapter 5 Blood pressure management in children with CKD Clinical question In children with CKD, does a lower BP target compared to a higher BP target improve ef cacy outcomes and reduce adverse effects? 